PLATIPUS will host domains in pregnancy and early life (the ‘neonatal’ period).
Pregnancy Domains will assess therapies in pregnant women at risk of preterm birth. If you are pregnant and at risk of having your baby early, find out more about currently active Pregnancy Domains below.
Neonatal Domains will assess therapies for babies born preterm. If you are a parent or caregiver of a preterm baby, find out more about currently active Neonatal Domains below.
Objective
To determine which antibiotic regimen given to pregnant women and people with preterm prelabour rupture of membranes (PPROM) is best at improving health outcomes for preterm infants.
Who will be eligible?
Pregnant women and people with preterm, prelabour rupture of membranes (PPROM) who meet the eligibility criteria and are receiving care at a hospital taking part in this trial.
Why is this important?
Preterm prelabour rupture of membranes (PPROM) is when a pregnant woman or person’s waters break early. Approximately 30-40% of women who go on to have a preterm birth experience PPROM. PPROM can lead to infections and other complications in mother and baby.
Antibiotics are routinely given to pregnant women and people who experience PPROM to reduce the risk of infection.
Why are we doing this study?
The antibiotics given after PPROM vary in Australia, Aotearoa New Zealand and worldwide. Evidence for some of these antibiotics is now quite old, and there is potential in other antibiotics that are already being used for this purpose.
PROMOAT will assess three common antibiotic regimens given after PPROM in Australia and Aotearoa New Zealand, to reduce uncertainty and understand which antibiotic is best in reducing the risk of infection in mother and baby.
Funder: NHMRC and MRFF
Ethics Reference: [Pending]
Trial Registration: [Pending]
Lead Investigators: Associate Professor Clare Whitehead and Professor Katie Groom
Objective
To determine the optimal dose of caffeine citrate for very preterm infants experiencing apnoea of prematurity (breathing problems).
Who will be eligible?
Very preterm infants (babies born less than 32 weeks gestation) who meet the eligibility criteria and are receiving care at a hospital taking part in this trial.
Why is this important?
Apnoea of prematurity is when a baby born preterm stops breathing intermittently. It is common in preterm babies and occurs in almost all babies born at less than 28 weeks gestation.
Caffeine is routinely given to preterm babies who experience apnoea of prematurity. Caffeine has been shown to reduce both the number of times a baby stops breathing, and the number of babies who need additional help to breathe. This is important as it may also help to reduce the risk of other complications after birth and in the future.
Why are we doing this study?
The optimal dose of caffeine is unknown, and caffeine dosing practices vary in Australia, Aotearoa New Zealand and worldwide.
BabyCCINO will assess three common caffeine doses and dosing regimens that are given to babies born preterm in Australia and Aotearoa New Zealand, to reduce uncertainty and understand which dose is best for babies who experience apnoea of prematurity.
Funder: NHMRC and MRFF
Ethics Reference: [Pending]
Trial Registration: [Pending]
Lead Investigators: Professor Brett Manley and Associate Professor Chris McKinlay
